The DOI matches its Crossref record.
Importance of DNase and alginate lyase for enhancing free and liposome encapsulated aminoglycoside activity against Pseudomonas aeruginosa
Abstract
OBJECTIVES: This study evaluated the potential of DNase, alginate lyase (AlgL) and N-acetylcysteine (NAC) in enhancing the in vitro bactericidal activity of conventional (free) and vesicle-entrapped (liposomal) gentamicin, amikacin and tobramycin. METHODS: The MICs and biofilm eradication for two clinical isolates of Pseudomonas aeruginosa (a mucoid strain and a non-mucoid strain) were determined in the presence and absence of AlgL. The co-activity of aminoglycosides with DNase and/or AlgL against endogenous P. aeruginosa in cystic fibrosis (CF) sputum was also measured. The inhibitory effects of mucin in the presence and absence of the mucolytic agent NAC on aminoglycosidic activity were also examined. RESULTS: The MIC values of the liposomal aminoglycosides were similar to or lower than those of free aminoglycosides. Biofilm formation increased the bactericidal concentrations of these drugs by 8- to 256-fold and treatment with AlgL improved killing of the mucoid strain. The activity of some aminoglycosides against the sputum was increased by the addition of DNase or AlgL (P < 0.05), and was increasingly evident with concurrent DNase and AlgL administration. Addition of mucin inhibited liposomal aminoglycosidic activity (up to 32-fold) evidently more than the free aminoglycosides (up to 8-fold). The addition of NAC did not improve activity significantly (P > 0.05). Tobramycin was the most effective aminoglycoside to reduce biofilms and sputum. CONCLUSIONS: Liposomal aminoglycosides do not fare better than conventional forms. The co-administration of DNase and AlgL is essential for enhanced activity in reducing biofilm growth and sputum bacterial counts. While mucin retards bactericidal activity, NAC does not improve aminoglycosidic activity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Antibiotic resistance of bacterial biofilms
Høiby, N., Bjarnsholt, T., Givskov, M., Molin, S., & Ciofu, O. (2010) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2009.12.011 · Cited by 3,225
The role of bacterial biofilms in chronic infections
Bjarnsholt, T. (2013) · APMIS · doi:10.1111/apm.12099 · Cited by 1,080
Biofilm Dispersal: Mechanisms, Clinical Implications, and Potential Therapeutic Uses
Kaplan, J. B. (2010) · Journal of Dental Research · doi:10.1177/0022034509359403 · Cited by 949
Intrapleural Use of Tissue Plasminogen Activator and DNase in Pleural Infection
Rahman, N. M., Maskell, N. A., West, A., Teoh, R., Arnold, A., Mackinlay, C., Peckham, D., Davies, C. W. H., Ali, N., Kinnear, W., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1012740 · Cited by 855
Antibiotic alternatives: the substitution of antibiotics in animal husbandry?
Cheng, G., Hao, H., Xie, S., Wang, X., Dai, M., Huang, L., & Yuan, Z. (2014) · Frontiers in Microbiology · doi:10.3389/fmicb.2014.00217 · Cited by 622
Antimicrobial susceptibility testing in biofilm-growing bacteria
Macia, M. D., Rojo-Molinero, E., & Oliver, A. (2014) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12651 · Cited by 537
Applying insights from biofilm biology to drug development — can a new approach be developed?
Bjarnsholt, T., Ciofu, O., Molin, S., Givskov, M., & Høiby, N. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4000 · Cited by 516
Antimicrobial Photodynamic Therapy to Control Clinically Relevant Biofilm Infections
Hu, X., Huang, Y.-Y., Wang, Y., Wang, X., & Hamblin, M. R. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.01299 · Cited by 502
Lipid and polymer nanoparticles for drug delivery to bacterial biofilms
Forier, K., Raemdonck, K., De Smedt, S. C., Demeester, J., Coenye, T., & Braeckmans, K. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.03.055 · Cited by 464
An update on Pseudomonas aeruginosa biofilm formation, tolerance, and dispersal
Harmsen, M., Yang, L., Pamp, S. J., & Tolker-Nielsen, T. (2010) · FEMS Immunology & Medical Microbiology · doi:10.1111/j.1574-695x.2010.00690.x · Cited by 376
Billings, N., Ramirez Millan, M., Caldara, M., Rusconi, R., Tarasova, Y., Stocker, R., & Ribbeck, K. (2013) · PLoS Pathogens · doi:10.1371/journal.ppat.1003526 · Cited by 326
Ciofu, O., Tolker-Nielsen, T., Jensen, P. Ø., Wang, H., & Høiby, N. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2014.11.017 · Cited by 306
Nanotechnology-based drug delivery systems for control of microbial biofilms: a review
Dos Santos Ramos, M. A., Da Silva, P., Spósito, L., De Toledo, L., Bonifácio, B., Rodero, C. F., Dos Santos, K., Chorilli, M., & Bauab, T. M. (2018) · International Journal of Nanomedicine · doi:10.2147/ijn.s146195 · Cited by 277
Otter, J. A., Vickery, K., Walker, J. T., deLancey Pulcini, E., Stoodley, P., Goldenberg, S. D., Salkeld, J. A. G., Chewins, J., Yezli, S., & Edgeworth, J. D. (2015) · Journal of Hospital Infection · doi:10.1016/j.jhin.2014.09.008 · Cited by 263
Reighard, K. P., Hill, D. B., Dixon, G. A., Worley, B. V., & Schoenfisch, M. H. (2015) · Biofouling · doi:10.1080/08927014.2015.1107548 · Cited by 53
Metadata
- Authors
- Alipour, M., Suntres, Z. E., & Omri, A.
- Venue
- Journal of Antimicrobial Chemotherapy
- Publisher
- Oxford University Press (OUP)
- Published
- 2009-05-22
- Volume
- 64
- Issue
- 2
- Pages
- 317-325
- ISSN
- 0305-7453 (ISSN-L)
- 1460-2091
- OpenAlex
- W2127778188
- Cited by
- 161
- References
- 0
- FWCI
- 2.52
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.